.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,910,031

« Back to Dashboard

Details for Patent: 7,910,031

Title:Process for forming an ingestible thin film with non-self-aggregating uniform heterogeneity
Abstract: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.
Inventor(s): Yang; Roert K. (Flushing, NY), Fuisz; Richard C. (McLean, VA), Myers; Garry L. (Kingsport, TN), Fuisz; Joseph M. (Washington, DC)
Assignee: Monosol Rx, LLC (Portage, IN)
Filing Date:Mar 26, 2009
Application Number:12/411,835
Claims:1. A process for forming an ingestible film having a substantially uniform distribution of components comprising at least one anti-emetic compound, comprising the steps of: (a) combining a polymer component, water and at least one anti-emetic compound to form a matrix with a substantially uniform distribution of said components; (b) forming a film from said matrix; (c) providing a conveyor surface having top and bottom sides; (d) feeding said film onto said top side of said surface; and (e) drying said film within about 10 minutes or fewer by applying hot air currents to said bottom side of said conveyor surface and exposing said film to a temperature above the degradation temperature of said anti-emetic compound, wherein said degradation temperature is 70.degree. C. or higher.

2. A process for forming an ingestible film having a substantially uniform distribution of components comprising an active comprising at least one anti-emetic compound, comprising the steps of: (a) combining a polymer component, a solvent, and at least one anti-emetic compound to form a matrix with a substantially uniform distribution of said components; (b) forming a film from said matrix; (c) providing a conveyor surface having top and bottom sides; (d) feeding said film onto said top side of said surface; and (e) drying said film within about 10 minutes or fewer using hot air currents to at least said bottom side of said conveyor surface to lock in said substantially uniform distribution of components without degradation of said anti-emetic compound, said air currents having a temperature of at least 60.degree. C.

3. A process for forming an ingestible film having a substantially uniform distribution of components comprising at least one anti-emetic compound, comprising the steps of: (a) forming a master batch premix of a polymer component and a solvent; (b) feeding a predetermined amount of said premix to at least one mixer; (c) adding at least one anti-emetic compound to said at least one mixer; (d) mixing said anti-emetic compound and said predetermined amount of said premix to form a matrix having a substantially uniform distribution of components; (e) forming a film from said matrix; (f) providing a conveyor surface having top and bottom sides; (g) feeding said film onto said top side of said surface; and (h) drying said film using heat applied to at least said bottom side of said conveyor surface such that the components of said film are heated to a temperature at least 60.degree. C., without degradation of said anti-emetic compound, wherein said drying step comprises rapidly forming a visco-elastic film within about the first 4.0 minutes by applying hot air currents to at least said bottom side of said surface to lock in said substantially uniform distribution of components; and drying said visco-elastic film to form a self-supporting ingestible film having a substantially uniform distribution of components.

4. The process of claim 2, wherein said drying step maintains a non-self-aggregating uniform heterogeneity of said components throughout said film.

5. The process of claim 2, wherein said film is self-supporting.

6. The process of claim 2, wherein a specific amount of said anti-emetic compound is obtained from said film by cutting said film to a predetermined size.

7. The process of claim 2, wherein a specific amount of said anti-emetic compound is obtained from said film by cutting said film to a predetermined weight.

8. The process of claim 2, wherein said drying of said film reduces the weight percent of said solvent to about 10% or less.

9. The process of claim 2, wherein said drying of said film reduces the weight percent of said solvent to about 6% or less.

10. The process of claim 2, wherein said solvent comprises a polar solvent.

11. The process of claim 10, wherein said solvent comprises a mixture of polar solvents.

12. The process of claim 2, wherein said polymer is water soluble.

13. The process of claim 2, wherein said polymer is an edible polymer.

14. The process of claim 2, wherein said polymer component, said active comprising at least one anti-emetic compound, and said solvent are each ingestible materials.

15. The process of claim 2, wherein said active comprising at least one anti-emetic compound is in the form of a particle.

16. The process of claim 2, wherein said matrix comprises an emulsion, a colloid or a suspension.

17. The process of claim 2, wherein said matrix comprises a dispersion.

18. The process of claim 2, wherein said matrix comprises at least one taste-masking agent.

19. The process of claim 2, wherein said active comprising at least one anti-emetic compound is in a controlled release form.

20. The process of claim 2, wherein said ingestible film releases said active comprising at least one anti-emetic compound over an extended period of time.

21. The process of claim 2, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through the buccal cavity of said individual.

22. The process of claim 2, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through a mucosal surface of said individual.

23. The process of claim 2, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through sublingual application.

24. The process of claim 2, wherein said ingestible film is orally administrable.

25. The process of claim 2, wherein said ingestible film has a substantially uniform thickness.

26. The process of claim 2, wherein the ingestible film has a variation of active content of less than 10% per film unit.

27. The process of claim 2, further comprising the step of forming a plurality of individual dosage units of substantially the same size, wherein the active content of individual dosage units has a variance of no more than 10%.

28. The process of claim 2, further comprising the step of deaerating said matrix.

29. The process of claim 2, wherein said matrix is formed via a process comprising the steps of: (a) Forming a master batch premix comprising said polymer and said solvent; (b) Directing said premix and said anti-emetic compound to at least one mixer; and (c) Mixing said premix and anti-emetic compound to form said matrix.

30. The process of claim 2, wherein said process prevents substantial aggregation of said active comprising at least one anti-emetic compound.

31. The process of claim 2, wherein any air flow present during said step of drying does not overcome the inherent viscosity of said film.

32. The process of claim 2, wherein said hot air currents are provided by radiation energy.

33. The process of claim 2, wherein said radiation energy comprises infrared energy, radio frequency radiation, or microwave energy.

34. The process of claim 2, wherein said step of forming a film from said matrix comprises casting said matrix.

35. The process of claim 2, wherein said step of forming a film from said matrix comprises extruding said matrix.

36. The process of claim 2, wherein said step of forming a film from said matrix comprises forming a wet film in the form of a sheet.

37. The process of claim 2, wherein said active comprising at least one anti-emetic compound comprises at least one anti-nauseant.

38. The process of claim 2, wherein said anti-emetic compound comprises granisetron.

39. The process of claim 1, wherein said drying step maintains a non-self-aggregating uniform heterogeneity of said components throughout said film.

40. The process of claim 1, wherein said film is self-supporting.

41. The process of claim 1, wherein a specific amount of said anti-emetic compound is obtained from said film by cutting said film to a predetermined size.

42. The process of claim 1, wherein a specific amount of said anti-emetic compound is obtained from said film by cutting said film to a predetermined weight.

43. The process of claim 1, wherein said drying of said film reduces the weight percent of said solvent to about 10% or less.

44. The process of claim 1, wherein said drying of said film reduces the weight percent of said solvent to about 6% or less.

45. The process of claim 1, wherein said solvent comprises a polar solvent.

46. The process of claim 45, wherein said solvent comprises a mixture of polar solvents.

47. The process of claim 1, wherein said polymer is water soluble.

48. The process of claim 1, wherein said polymer is an edible polymer.

49. The process of claim 1, wherein said polymer component, said active comprising at least one anti-emetic compound, and said solvent are each ingestible materials.

50. The process of claim 1, wherein said active comprising at least one anti-emetic compound is in the form of a particle.

51. The process of claim 1, wherein said matrix comprises an emulsion, a colloid or a suspension.

52. The process of claim 1, wherein said matrix comprises a dispersion.

53. The process of claim 1, wherein said matrix comprises at least one taste-masking agent.

54. The process of claim 1, wherein said active comprising at least one anti-emetic compound is in a controlled release form.

55. The process of claim 1, wherein said ingestible film releases said active comprising at least one anti-emetic compound over an extended period of time.

56. The process of claim 1, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through the buccal cavity of said individual.

57. The process of claim 1, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through a mucosal surface of said individual.

58. The process of claim 1, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through sublingual application.

59. The process of claim 1, wherein said ingestible film is orally administrable.

60. The process of claim 1, wherein said ingestible film has a substantially uniform thickness.

61. The process of claim 1, wherein the ingestible film has a variation of active content of less than 10% per film unit.

62. The process of claim 1, further comprising the step of forming a plurality of individual dosage units of substantially the same size, wherein the active content of individual dosage units has a variance of no more than 10%.

63. The process of claim 1, further comprising the step of deaerating said matrix.

64. The process of claim 1, wherein said matrix is formed via a process comprising the steps of: (a) Forming a master batch premix comprising said polymer and said solvent; (b) Directing said premix and said anti-emetic compound to at least one mixer; and (c) Mixing said premix and anti-emetic compound to form said matrix.

65. The process of claim 1, wherein said process prevents substantial aggregation of said active comprising at least one anti-emetic compound.

66. The process of claim 1, wherein any air flow present during said step of drying does not overcome the inherent viscosity of said film.

67. The process of claim 1, wherein said hot air currents are provided by radiation energy.

68. The process of claim 67, wherein said radiation energy comprises infrared energy, radio frequency radiation, or microwave energy.

69. The process of claim 1, wherein said step of forming a film from said matrix comprises casting said matrix.

70. The process of claim 1, wherein said step of forming a film from said matrix comprises extruding said matrix.

71. The process of claim 1, wherein said step of forming a film from said matrix comprises forming a wet film in the form of a sheet.

72. The process of claim 1, wherein said active comprising at least one anti-emetic compound comprises at least one anti-nauseant.

73. The process of claim 1, wherein said anti-emetic compound comprises granisetron.

74. The process of claim 3, wherein said drying step maintains a non-self-aggregating uniform heterogeneity of said components throughout said film.

75. The process of claim 3, wherein said ingestible film is self-supporting.

76. The process of claim 3, wherein a specific amount of said anti-emetic compound may be obtained from said film by cutting said film to a predetermined size.

77. The process of claim 3, wherein a specific amount of said anti-emetic compound may be obtained from said film by cutting said film to a predetermined weight.

78. The process of claim 3, wherein said drying of said film reduces the weight percent of said solvent to about 10% or less.

79. The process of claim 3, wherein said drying of said film reduces the weight percent of said solvent to about 6% or less.

80. The process of claim 3, wherein said solvent comprises a polar solvent.

81. The process of claim 80, wherein said solvent comprises a mixture of polar solvents.

82. The process of claim 3, wherein said polymer is water soluble.

83. The process of claim 3, wherein said polymer is an edible polymer.

84. The process of claim 3, wherein said polymer component, said active comprising at least one anti-emetic compound, and said solvent are each ingestible materials.

85. The process of claim 3, wherein said active comprising at least one anti-emetic compound is in the form of a particle.

86. The process of claim 3, wherein said matrix comprises an emulsion, a colloid or a suspension.

87. The process of claim 3, wherein said matrix comprises a dispersion.

88. The process of claim 3, wherein said matrix comprises at least one taste-masking agent.

89. The process of claim 3, wherein said active comprising at least one anti-emetic compound is in a controlled release form.

90. The process of claim 3, wherein said ingestible film releases said active comprising at least one anti-emetic compound over an extended period of time.

91. The process of claim 3, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through the buccal cavity of said individual.

92. The process of claim 3, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through a mucosal surface of said individual.

93. The process of claim 3, wherein said ingestible film is capable of providing administration of said active comprising at least one anti-emetic compound to an individual through sublingual application.

94. The process of claim 3, wherein said ingestible film is orally administrable.

95. The process of claim 3, wherein said ingestible film has a substantially uniform thickness.

96. The process of claim 3, wherein the ingestible film has a variation of active content of less than 10% per film unit.

97. The process of claim 3, further comprising the step of forming a plurality of individual dosage units of substantially the same size, wherein the active content of individual dosage units has a variance of no more than 10%.

98. The process of claim 3, further comprising the step of deaerating said matrix.

99. The process of claim 3, wherein said process prevents substantial aggregation of said active comprising at least one anti-emetic compound.

100. The process of claim 3, wherein any air flow present during said step of drying does not overcome the inherent viscosity of said film.

101. The process of claim 3, wherein said hot air currents are provided by radiation energy.

102. The process of claim 101, wherein said radiation energy comprises infrared energy, radio frequency radiation, or microwave energy.

103. The process of claim 3, wherein said step of forming a film from said matrix comprises casting said matrix.

104. The process of claim 3, wherein said step of forming a film from said matrix comprises extruding said matrix.

105. The process of claim 3, wherein said step of forming a film from said matrix comprises forming a wet film in the form of a sheet.

106. The process of claim 3, wherein said active comprising at least one anti-emetic compound comprises at least one anti-nauseant.

107. The process of claim 3, wherein said anti-emetic compound comprises granisetron.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc